Charles River Laboratories International, Inc. (NYSE:CRL) CEO James C. Foster Acquires 6,075 Shares

Charles River Laboratories International, Inc. (NYSE:CRL) CEO James C. Foster bought 6,075 shares of the company’s stock in a transaction on Thursday, February 20th. The shares were acquired at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the acquisition, the chief executive officer now directly owns 183,639 shares in the company, valued at $30,302,271.39. This represents a 3.42 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Charles River Laboratories International Price Performance

CRL opened at $163.11 on Friday. The company’s 50 day simple moving average is $172.84 and its 200 day simple moving average is $188.37. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. Charles River Laboratories International, Inc. has a 1 year low of $150.79 and a 1 year high of $275.00. The stock has a market capitalization of $8.34 billion, a PE ratio of 1,087.39, a P/E/G ratio of 6.77 and a beta of 1.37.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.50 by $0.16. The business had revenue of $1 billion for the quarter, compared to analysts’ expectations of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company’s quarterly revenue was down 1.1% on a year-over-year basis. During the same period last year, the company earned $2.46 earnings per share. As a group, sell-side analysts expect that Charles River Laboratories International, Inc. will post 9.41 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have weighed in on CRL shares. Robert W. Baird dropped their target price on shares of Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating for the company in a report on Thursday. Barclays lowered their price target on shares of Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating for the company in a report on Tuesday. JPMorgan Chase & Co. lowered their price target on shares of Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating for the company in a report on Thursday. Evercore ISI lifted their price target on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a report on Thursday, November 7th. Finally, The Goldman Sachs Group lowered their price target on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating for the company in a report on Thursday, January 23rd. Three analysts have rated the stock with a sell rating, thirteen have given a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $195.71.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Empirical Finance LLC lifted its position in Charles River Laboratories International by 4.2% during the third quarter. Empirical Finance LLC now owns 1,310 shares of the medical research company’s stock valued at $258,000 after buying an additional 53 shares in the last quarter. Fiduciary Financial Group LLC lifted its position in Charles River Laboratories International by 3.9% during the fourth quarter. Fiduciary Financial Group LLC now owns 1,665 shares of the medical research company’s stock valued at $310,000 after buying an additional 63 shares in the last quarter. Pinnacle Bancorp Inc. lifted its position in Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after buying an additional 65 shares in the last quarter. M&T Bank Corp lifted its position in Charles River Laboratories International by 3.4% during the third quarter. M&T Bank Corp now owns 2,001 shares of the medical research company’s stock valued at $394,000 after buying an additional 66 shares in the last quarter. Finally, Cornerstone Investment Partners LLC lifted its position in Charles River Laboratories International by 3.7% during the fourth quarter. Cornerstone Investment Partners LLC now owns 1,940 shares of the medical research company’s stock valued at $358,000 after buying an additional 69 shares in the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).